Research status of cognitive dysfunction after SARS-CoV-2 infection

doi:10.19803/j.1672-8629.20230695

Abstract

Abstract: Objective To review the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cognitive dysfunction and the mechanism of cognitive dysfunction in post-COVID-19 syndrome. Methods CNKI and PubMed databases were searched to collect relevant research reports on cognitive dysfunction after SARS-CoV-2 infection by traditional Chinese medicine (TCM) and western medicine from January 1, 2020 to October 30, 2023. Results Cognitive dysfunction might occur after SARS-CoV-2 infection, which might be related to the neuroaggressive, neurotropic, and neurovirulent nature of the SARS-CoV-2 virus, or to factors such as post-infection-mediated hyperinflammation, serotonin levels, and viral metastasis. It was also found that some TCM monomers had the effect of improving cognitive dysfunction after SARS-CoV-2 infection. Conclusion Cognitive dysfunction may occur for a short time or for a long time after SARS-CoV-2 infection, and its mechanism needs to be further verified by clinical and basic research.

Key words: severe acute respiratory syndrome coronavirus 2, post-COVID-19 syndrome, cognitive dysfunction, traditional Chinese medicine, nerve

CLC Number:

R978.7

LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan. Research status of cognitive dysfunction after SARS-CoV-2 infection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230695

https://www.zgywjj.com/EN/Y2024/V21/I1/59

References

[1] LI YC, BAI WZ, HIRANO N, et al.Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication[J]. J Comp Neurol, 2013, 521: 203-212.
[2] YAO JY, GUAN X, WEI WJ, et al.The neurotropic nature of the novel coronavirus causes nervous system damage and dysfunctio[J].Neural Injury and Functional Reconstruction(神经损伤与功能重建), 2023, 18(7): 427-431.
[3] HUANG C, WANG Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395: 497-506.
[4] RENAUD-CHAREST O, LUI LMW, ESKANDER S, et al.Onset and frequency of depression in post-COVID-19 syndrome: a systematic review[J]. J Psychiatr Res, 2021, 144: 129-137.
[5] HE XD, ZHANG LS, ZHENG X, et al.Investigation of neurological symptoms in patients with novel coronavirus pneumonia[C].Compilation of Papers of Zhejiang Provincial Neurology Academic Conference in 2020: 161.
[6] SORIANO JB, MURTHY S, MARSHALL JC, et al.A clinical case definition of post-COVID-19 condition by a Delphi consensus[J].Lancet Infect Dis, 2022, 22(4): e102-e107.
[7] SONG E, ZHANG C, ISRAELOW B, et al.Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19[J]. Neuropsychopharmacology, 2021, 46(13): 2235-2240.
[8] ALENINA N, BADER M.ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models[J].Neurochem Res, 2019, 44(6): 1323-1329.
[9] SONG E, ZHANG C, ISRAELOW B, et al.Neuroinvasion of SARS-CoV-2 in human and mouse brain[J]. J Exp Med, 2021, 218(3): e20202135.
[10] RAMANI A, PRANTY AI, GOPALAKRISHNAN J.Neurotropic effects of SARS-CoV-2 modeled by the human brain organoids[J].Stem Cell Reports, 2021, 16(3): 373-384.
[11] LI MY, LI L, ZHANG Y.Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J].Infect Dis Poverty, 2020, 9(1): 45.
[12] CHEN XL, LAURENT S, ONUR OA, et al.A systematic review of neurological symptoms and complications of COVID-19[J]. J Neurol, 2021, 268(2): 392-402.
[13] BEACH SR, PRASCHAN NC, HOGAN C, et al.Delirium in COVID-19: a case series and exploration of potential mechanisms for central nervous system involvement[J]. Gen Hosp Psychiatry, 2020, 65: 47-53.
[14] ALEMANNO F, HOUDAYER E, PARMA A, et al.COVID-19 cognitive deficits after respiratory assistance in the subacute phase: a COVID rehabilitation unit experience[J]. PLoS One, 2021, 16(2): e0246590.
[15] ASANOVA A, KHAUSTOVA O, ABDRIAKHIMOV R, et al.Cognitive impairment in patients hospitalized with COVID-19 pneumonia: correlation with demographic, clinical and emotional profile[J]. Wiad Lek, 2022, 75(8 pt 1): 1868-1875.
[16] ATCHISON CJ, DAVIES B, COOPER E, et al.Long-term health impacts of COVID-19 among 242 712 adults in England[J]. Nat Commun, 2023, 14(1): 6588.
[17] FURMAN S, GREEN K, LANE TE. COVID-19 and the impact on Alzheimer’s disease pathology[J/OL]. J Neurochem,(2023-10-18)[2023-11-03]. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jnc.159.
[18] The Lancet Neurology.Long COVID: understanding the neurological effects[J]. Lancet Neurol, 2021, 20(4): 247.
[19] MISKOWIAK KW, JOHNSEN S, SATTLER SM, et al.Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables[J]. Eur Neuropsychopharmacol, 2021, 46: 39-48.
[20] VALERIE B, SONIA CH, VINCENT D, et al.Pattern of cognitive deficits in severe COVID-19[J]. J Neurol Neurosurg Psychiatry, 2021, 92(5): 567-568.
[21] MISKOWIAK KW, FUGLEDALEN L, JESPERSEN AE, et al.Trajectory of cognitive impairments over 1 year after COVID-19 hospitalisation: pattern, severity, and functional implications[J]. Eur Neuropsychopharmacol, 2022, 59: 82-92.
[22] TAVARES-JUNIOR JWL, DE-SOUA ACC, BORGES JWP, et al.COVID-19 associated cognitive impairment: a systematic review[J]. Cortex, 2022, 152: 77-97.
[23] ZHANG DY, RASS V.Neurological sequelae a year after the diagnosis of COVID-19[J]. Rehabilitation in China(中国康复), 2022, 37(8): 492.
[24] TAQUET M, GEDDES JR, HUSAIN M, et al.6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records[J]. Lancet Psychiatry, 2021, 8: 416-427.
[25] LI C, LIU J, LIN J, et al.COVID-19 and risk of neurodegenerative disorders: a Mendelian randomization study[J]. Transl Psychiatry, 2022, 12(1): 283.
[26] DUBEY S, DAS S, GHOSH R, et al.the effects of sars-cov-2 infection on the cognitive functioning of patients with pre-existing dementia[J]. J Alzheimers Dis Rep, 2023, 7(1): 119-128.
[27] GROISS SJ, BALLOFF C, ELBEN S, et al.Prolonged neuropsychological deficits, central nervous system involvement, and brain stem affection after COVID-19: a case series[J]. Front Neurol, 2020, 11: 574004.
[28] AMALAKANTI S, AREPALLI KVR, JILLELLA JP.Cognitive assessment in asymptomatic COVID-19 subjects[J]. Virusdisease, 2021, 32: 146-149.
[29] BAUER L, LAKSONO BM, DE VRIJ FMS, et al.The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2[J]. Trends Neurosci, 2022, 45: 358-368.
[30] CRIVELLI L, PALMER K, CALANDRI I, et al.Changes in cognitive functioning after COVID-19: a systematic review and meta-analysis[J]. Alzheimers Dement, 2022, 18(5): 1047-1066.
[31] BAUER L, LAKSONO BM, DE VRIJ FMS, et al.The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2[J]. Trends Neurosci, 2022, 45(5): 358-368.
[32] DESFORGES M, COUPANEC AL, DUBEAU P, et al.Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?[J]. Viruses, 2019, 12(1): 14.
[33] SUZUKI M, SAITO K, MIN WP, et al.Identification of viruses in patients with postviral olfactory dysfunction[J]. Laryngoscope, 2007, 117(2): 272-277.
[34] LUDLOW M, KORTEKAAS J, HERDEN C, et al.Neurotropic virus infections as the cause of immediate and delayed neuropathology[J].Acta Neuropathol, 2016, 131(2): 159-184.
[35] MEINHARDT J, RADKE J, DITTMAYER C, et al.Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19[J]. Nat Neurosci, 2021, 24(2): 168-175.
[36] MESSLINGER K, NEUHUBER W, MAY A.Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19[J]. Cephalalgia, 2022, 42(2): 176-180.
[37] BULFAMANTE G, BOCCI T, FALLENI M, et al.Brainstem neuropathology in two cases of COVID-19: SARS-CoV-2 trafficking between brain and lung[J]. J Neurol, 2021, 268(12): 4486-4491.
[38] WENZEL J, LAMPE J, MULLER-FIELITZ H, et al.The SARS-CoV-2 main protease M^procauses microvascular brain pathology by cleaving NEMO in brain endothelial cells[J]. Nat Neurosci, 2021, 24(11): 1522-1533.
[39] KRASEMANN S, HAFERKAMP U, PFEFFERLE S, et al.The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2[J]. Stem Cell Reports, 2022, 17(2): 307-320.
[40] GOMES I, KARMIRIAN K, OLIVEIRA JT, et al.SARS-CoV-2 infection of the central nervous system in a 14-month-old child: A case report of a complete autopsy[J]. Lancet Reg Heal Am, 2021, 2: 100046.
[41] FERREN M, FAVEDE V, DECIMO D, et al.Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection[J]. Nat Commun, 2021, 12(1): 5809.
[42] HAN YL, YANG LL, KIM TW, et al. SARS-CoV-2 infection causes dopaminergic neuron senescence[J/OL]. Res Sq,(2021-05-21)[2023-11-03]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142658/.
[43] COSENTINO G, TODISCO M, HOTA N, et al.Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: a critical systematic review[J]. Eur J Neurol, 2021, 28(11): 3856-3865.
[44] SOLOMON IH, NORMANDIN E, BHATTACHARYYA S, et al.Neuropathological features of Covid-19[J]. N Engl J Med, 2020, 383: 989-992.
[45] LEE MH, PERL DP, NAIR G, et al.Microvascular injury in the brains of patients with COVID-19[J]. N Engl J Med, 2021, 384(5): 481-483.
[46] DE SOUSA VL, ARAUJO SB, ANTONIO LM, et al.Innate immune memory mediates increased susceptibility to Alzheimeŕs disease-like pathology in sepsis surviving mice. Brain Behav[J]. Immun, 2021, 95: 287-298.
[47] FIGUEIREDO CP, BARROS-ARAGAO FGQ, NERIS RLS, et al.Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice[J]. Nat Commun, 2019, 10(1): 3890.
[48] HICKMAN S, IZZY S, SEN P, et al.Microglia in neurodegeneration[J].Nat Neurosci, 2018, 21: 1359-1369.
[49] FROST PS, BARROS-ARAGAO F, DA SILAVA RT, et al.Neonatal infection leads to increased susceptibility to Aβ oligomer-induced brain inflammation, synapse loss and cognitive impairment in mice[J]. Cell Death Dis, 2019, 10(4): 323.
[50] VASEK MJ, GARBER C, DORSEY D, et al.A complement-microglial axis drives synapse loss during virus-induced memory impairment[J]. Nature, 2016, 534(7648): 538-543.
[51] MATIAS I, MORGADO J, GOMES FCA.Astrocyte heterogeneity: impact to brain aging and disease[J]. Front Aging Neurosci, 2019, 11: 59.
[52] LIDDELOW SA, GUTTENPLAN KA, CLARKE LE, et al.Neurotoxic reactive astrocytes are induced by activated microglia[J].Nature, 2017, 541(7638): 481-487.
[53] SOUNG A, KLEIN RS.Viral encephalitis and neurologic diseases: focus on astrocytes[J]. Trends Mol Med, 2018, 24(11): 950-962.
[54] GARBER C, SOUNG A, VOLLMER LL, et al.T cells promote microglia-mediated synaptic elimination and cognitive dysfunction during recovery from neuropathogenic flaviviruses[J]. Nat Neurosci, 2019, 22(8): 1276-1288.
[55] HOSSEINI S, MICHAELSEN-PREUSSE K, GRIGORYAN G, et al.Type I interferon receptor signaling in astrocytes regulates hippocampal synaptic plasticity and cognitive function of the healthy CNS[J]. Cell Rep, 2020, 31(7): 107666.
[56] SOUZA ID, FROST PS, FRANCA JV, et al. Acute and chronic neurological consequences of early-life Zika virus infection in mice[J]. Sci Transl Med, 2018, 10(444): eaar2749.
[57] KELLY KM, SMITH JA, MEZUK B.Depression and interleukin-6 signaling: a mendelian randomization study[J]. Brain, Behavior, and Immunity, 2021, 95: 106-114.
[58] LOURENCO MV, CLARKE JR, FROZZA RL, et al.TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys[J]. Cell Metabol, 2013, 18(6): 831-843.
[59] WONG AC, DEVASON AS, UMANA IC, et al.Serotonin reduction in post-acute sequelae of viral infection[J]. Cell, 2023, 186(22): 4851-4867, e20.
[60] STEFANO GB, PTACEK R, PTACKOVA H, et al.Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce‘brain fog’ and results in behavioral changes that favor viral survival[J]. Med Sci Monit, 2021, 27: e930886.
[61] ESCH T, STEFANO GB, PTACEK R, et al.Emerging roles of blood-borne intact and respiring mitochondria as bidirectional mediators of pro- and anti-inflammatory processes[J]. Med Sci Monit, 2020, 26: e924337.
[62] MA QL, YAO CL, WU Y, et al. Neurological disorders after severe pneumonia are associated with translocation of endogenous bacteria from the lung to the brain[J]. Sci Adv, 2023, 9(42): eadi0699.
[63] GOMAA AA, ABDEL-WADOOD YA, GOMAA MA.Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment[J]. Inflammopharmacology, 2022, 30(6): 1977-1992.
[64] GONG Y, JIANG X, YANG S, et al.The biological activity of 3-O-acetyl-11-keto-β-boswellic acid in nervous system diseases[J]. Neuromolecular Med, 2022, 24(4): 374-384.
[65] LIU W, HUANG S, LI Y, et al.Suppressive effect of glycyrrhizic acid against lipopolysaccharide-induced neuroinflammation and cognitive impairment in C57 mice via toll-like receptor 4 signaling pathway[J]. Food Nutr Res, 2019, 63(1): 1516.
[66] JIANG R, GAO J, SHEN J, et al.Glycyrrhizic acid improves cognitive levels of aging mice by regulating t/b cell proliferation[J]. Front Aging Neurosci, 2020, 12: 570116.
[67] GOMAA AA, MAKBOUL RM, AL-MOKHTAR MA, et al.Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines[J]. Biomed Pharmacother, 2019, 109: 281-292.
[68] BUCCELLATO FR, DANCA M, FENOGLIPO C, et al.Role of oxidative damage in Alzheimer's disease and neurodegeneration: from pathogenic mechanisms to biomarker discovery[J]. Antioxidants(Basel), 2021, 10(9): 1353.
[69] LIN F, SHAN W, ZHENG Y, et al.Toll-like receptor 2 activation and up-regulation by high mobility group box-1 contribute to post-operative neuroinflammation and cognitive dysfunction in mice[J]. J Neurochem, 2021, 158(2): 328-341.
[70] SIDDIQUI A, SHAH Z, JAHAN RN, et al.Mechanistic role of boswellic acids in Alzheimer's disease: emphasis on anti-inflammatory properties[J]. Biomed Pharmacother, 2021, 144: 112250.
[71] MESHKAT S, MAHMOODI BS, RAJAEI S, et al.Boswellia serrata extract shows cognitive benefits in a double-blind, randomized, placebo-controlled pilot clinical trial in individuals who suffered traumatic brain injury[J]. Brain Inj, 2022, 36(4): 553-559.
[72] SEDIGHI B, PARDAKHTY A, KAMALI H, et al.Effect of Boswellia papyrifera on cognitive impairment in multiple sclerosis[J]. Iran J Neurol, 2014, 13(3): 149-153.
[73] UDO AZ, MUHANNAD Y, BENEDIKT JB, et al.Alleviation of post-COVID-19 cognitive deficits by treatment with EGb 761^®: a case series[J]. Am J Case Rep, 2022, 23: e937094.
[74] SINGH M, JINDAL D, KUMAR R, et al.Molecular docking and network pharmacology interaction analysis of gingko biloba(EGB761) extract with dual target inhibitory mechanism in alzheimer's disease[J]. J Alzheimers Dis, 2023, 93(2): 705-726.
[75] WANG Y, HAN Q, ZHANG S, et al.New perspective on the immunomodulatory activity of ginsenosides: focus on effective therapies for post-COVID-19[J]. Biomed Pharmacother, 2023, 165: 115154.
[76] SOBRINO-RELANO S, BALBOA-BANDEIRA Y, PENA J, et al.Neuropsychological deficits in patients with persistent COVID-19 symptoms: a systematic review and meta-analysis[J]. Sci Rep, 2023, 13(1): 10309.
[77] ZHANG SM, WU JH.Recent advances in COVID-19 and Alzheimer's disease[J]. Practical Geriatrics(实用老年医学), 2023, 37(5): 521-523, 527.
[78] LI TY, JIA YJ, WANG YJ, et al.Research progress of treatment drugs for SARS-CoV-2[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(11): 1266-1271.